Background
==========

The increasing availability of molecular biology tools has revealed the coexistence of numerous processes during carcinogenesis, from imbalances in the cell cycle to the development of a neoplastic tissue with invasive characteristics. Extracellular matrix (ECM) proteins interact directly with cell surface receptors/adhesion molecules to initiate signal transduction pathways and modulate different processes \[[@B1]\] that participate in various cellular events such as adhesion, migration, proliferation, cell differentiation, apoptosis and angiogenesis \[[@B2]\]. Integrins appear to act as adhesion receptors for ECM proteins such as collagen, laminin and fibronectin, and also play a role in cell--cell adhesion \[[@B3]\].

Integrins display a heterodimeric structure composed of an α subunit, with a large extracellular domain containing various regions with cationic links and a short intracellular domain, and a β subunit, which has a large extracellular domain with repeated sequences of amino acids, containing a large number of cysteine residues. To date, 18 α subunits and eight β subunits have been identified \[[@B4],[@B5]\]. The majority of integrin binding occurs at its extracellular domain, with the peptide sequence Arg-Gly-Asp, which is present in many ECM proteins \[[@B6],[@B7]\], acting as a transmembrane connector between the extracellular ligand and the cytoplasmic environment, thus participating in bidirectional signaling by different cell types \[[@B8]\].

The role of integrins is to modulate adhesion phenomena that are implicated in processes such as cell growth and development, apoptosis, adhesion, migration, invasion, phagocytosis and cell morphology \[[@B9]-[@B11]\]. Studies by Von Lampe et al. \[[@B12]\] showed that the expression levels of α3 and α5 integrins were very low in adenomas, and absent in the majority of colorectal carcinomas (CRCs). In contrast, the α6 integrin maintains its expression in adenomas, but its expression levels are very low in malignancies with infiltrative growth characteristics, suggesting an association with CRC progression \[[@B12]\].

Some studies \[[@B13]\] have reported a crucial role for the αV integrin in the migration of cells in the colon, but the dynamics of this integrin and its effects are still poorly understood. Some integrins show different expression profiles during tumor growth and progression, suggesting their potential as targets for the diagnosis and therapy of cancer \[[@B14]-[@B16]\].

Methods
=======

Clinical characteristics
------------------------

This study included patients of either gender aged ≥18 years who underwent surgery at the Colorectal Surgery Department, Barretos Cancer Hospital, Brazil, between 2006 and 2009, and who had cryopreserved tumor samples obtained during surgery and paraffin-embedded tissue available for further histopathological analysis. Patients who had received neoadjuvant treatment (chemotherapy or radiotherapy), patients in whom the primary CRC site had not been removed, and patients with a previous or current diagnosis of other primary malignancies in any location of the body, other than non-melanoma skin cancer or cervical carcinoma *in situ*, were excluded from the study. A total of 114 patients with colon cancer (63 men, 51 women) were therefore included. Their median age was 54.5 years (range, 24--85 years). This study was approved by the Barretos Cancer Hospital Ethics Committee, São Paulo, Brazil. Project number: 128/2008.

The histological characteristics commonly associated with tumor dissemination and progression were categorized as follows: venous invasion (presence vs. absence), lymphatic vessel invasion (presence vs. absence), perineural invasion (presence vs. absence), lymph node metastasis (presence vs. absence), distant metastases (presence vs. absence), and TNM grouping ( I vs. II, I vs. III, I vs. IV , I: control group) (AJCC 2002, 6th edition).

To test the hypothesis that integrins might be associated with CRC progression and dissemination, we examined differences in their gene and protein expression levels with respect to the histological covariates mentioned above, using both reverse-transcription polymerase chain reaction (RT-PCR) and the immunohistochemical (IHC) tests using the tissue microarray technique (TMA). The use of human tissue for research was approved by the Institutional Review Board, and the design of this study followed the principles of the Helsinki Declaration and complied with the principles of good clinical practice. The clinical characteristics of the patients are presented in Table [1](#T1){ref-type="table"}.

Tumor specimens
---------------

Cryopreserved samples were embedded in medium for frozen tissue specimens (Tissue-Tek OCT; Sakura Finetek, Torrance, Calif., USA) and fitted into a cryostat (CM1850 UV; Leica Microsystems, Nussloch, Germany) for histological analysis. Slides mounted with sections of 4 μm thickness were subjected to the hematoxylin-eosin staining technique (Merck, Darmstadt, Germany) and then analyzed by a pathologist to ensure that the selected samples represented the general histology of the tumor and were free of necrosis or calcifications. Areas of interest were identified microscopically and marked for macrodissection. These slides were used as 'guides' to select and cut tissues in the cryostat. For each sample, sterile individual scalpel blades were used. After discarding inappropriate areas for RNA extraction, the tissue was mechanically macerated with liquid nitrogen and transferred to 1.5-ml microtubes, which were RNase and DNase free and contained 1,000 μl TRIzol (Invitrogen, Carlsbad, Calif., USA). RNA was extracted according to the manufacturer's instructions, and RNA quantification was performed using a spectrophotometer (Thermo Scientific NanoDrop 2000). The quality and integrity of the RNA were verified by the presence of 28S and 18S bands in agarose gel and stained with 1% ethidium bromide to assure the absence of degradation of the RNA samples.

###### 

Clinical characteristics of patients

          **Parameter**               **Number (%)**       
  ------------------------------ ------------------------- ------------
             Age (yr)                      \<60                 56
               \>60                         58             
               Sex                         Male             63 (55.3%)
              Female                    51 (44.7%)         
          Tumor location                   Colon            82 (71.9%)
              Rectum                    32 (28.1%)         
         Differentiation                   Well              9 (7.8%)
             Moderate                   91 (79.8%)         
               Poor                     14 (12.2%)         
         Histologic type              Adenocarcinoma        97 (85.1%)
        Mucinous carcinoma              17 (14.9%)         
   Histological characteristics   Inflammatory infiltrate   93 (81.6%)
       Perineural invasion               8 (7.1%)          
        Vascular invasion               21 (18.4%)         
           TNM staging                       I              25 (21.9%)
                II                      39 (34.2%)         
               III                      34 (29.8%)         
                IV                      16 (14.1%)         

![**Expression of integrins protein in CRC by IHC staining.** ( X 400). **A** , **C**, **E**, **G**, **I**, Low expression of α3, α5 , α6, αv, β5 integrins protein, respectively. **B**, **D**, **F**, **H** , **J**, Overexpression of α3, α5, α6, αv, β5 integrins protein respectively.](1472-6890-13-16-1){#F1}

RNA was purified with the RNeasy mini kit (Qiagen, Valencia, Calif., USA) following the manufacturer's recommendations, eluted with 30 ml of water free of RNase and DNase (Qiagen), quantified spectrophotometrically at a wavelength of 260 nm (NanoVue; GE Healthcare, Chicago, Ill., USA) and stored at -80°C until use. RT-PCR was performed using the Super- Script™ III first-strand synthesis SuperMix (Invitrogen), as recommended by the manufacturer. The reaction was carried out in a 20 μl final volume containing 2 μg of total RNA with oligo(dT)~20~ as a primer. The transcription phase was carried out in a thermal cycler (Mastercycler® ep Gradient S; Eppendorf, Hamburg, Germany), and the cDNA was stored at -20°C for future reactions.

###### 

Analysis of the expression of genes according to the categorization of covariates with descriptions of the fold regulation and statistical differences (Mann--Whitney U test; p values are shown in parentheses) in the study cohort (n = 114)

         **Covariates**          **Comparison performed**       **Genes**                                                                       
  ----------------------------- -------------------------- -------------------- --------------------- -------------------- -------------------- --------------------
             Gender                  Female vs. male         \- 1.81 (0.377)        1.20 (0.467)          1.22 (0.599)         1.04 (0.360)         1.17 (0.068)
               Age                  \<60 vs. ≥60 years         1.27 (0.301)      ***-1.54 (0.016)***      1.15 (0.524)         1.14 (0.267)        -1.22 (0.128)
   Histological classification     Adeno. vs. mucinous         4.02 (0.700)      ***1.25 (0.029)***      -1.05 (0.358)         1.34 (0.815)        -1.02 (0.983)
          Tumor grading             Low vs. high grade         2.94 (0.752)          1.88 (0.05)         -1.34 (0.098)         1.36 (0.889)         1.08 (0.371)
         Venous invasion            Absent vs. present         1.78 (0.653)         -1.13 (0.510)      ***1.42 (0.047)***      1.12 (0.718)         1.02 (0.818)
    Lymphatic vessel invasion       Absent vs. present         1.18 (0.619)         -1.47 (0.119)         1.10 (0.878)        -1.03 (0.643)        -1.03 (0.914)
       Perineural invasion          Absent vs. present        -4.11 (0.782)         1.00 (0.971)          1.36 (0.544)        -1.74 (0.686)      ***1.37 (0.028)***
      Clinical stage (TNM)              I vs. III           ***2.40 (0.025)***      1.08 (0.642)        \- 1.47 (0.869)     ***1.30 (0.042)***      1.14 (0.348)

*FR*, Fold regulation; *Adeno.*, Adenocarcinoma. Significant values are bold.

Analysis of genes of interest
-----------------------------

After RNA extraction and cDNA synthesis, tumor samples from the 114 cases of CRC were analyzed by RT-PCR for the amplification of 84 ECM genes using the Extracellular Matrix and Adhesion Molecules PCR Array plate (PAHS-013; SABiosciences, Qiagen, Valencia, CA, USA). Of these 84 genes, *ITGAV*, *ITGA3*, *ITGA5*, *ITGB5*, *ITGA6* were selected. Each sample was analyzed using an ECM and adhesion molecule PCR array (PAHS-013; SABiosciences, Qiagen) plate. A mixture was prepared containing 1.275 ml of buffer with SYBR Green (2× Master Mix SABiosciences RT2 qPCR), 1.173 ml RNAse-free H~2~O and 102 μl of the cDNA sample. Next, 25-μl aliquots were added to each well of the 96-well plate. Reactions were performed in a thermal cycler (ABI 7500; Applied Biosystems, Foster City, CA, USA), according to the following protocol: 95°C for 10 min, and 40 cycles at 95°C for 15 s and 60°C for 1 min. Data analysis was performed using the ΔΔCt method from the website <http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php>. Expression of each gene was classified as 'high' or 'low', based on the level of expression after grouping patients by the covariates of interest.

###### 

Description of the tissue expression of integrins according to categorization of IHC expression by TMA technique (n = 114)

   **Integrin**   **Low expression**   **High expression**       
  -------------- -------------------- --------------------- ---- ------
        α3                55                  48.2           59   51.8
       α 6                61                  53.5           53   46.5
       α 5                53                  46.5           61   53.5
       α V                62                  54.4           52   45.6
       β 5                63                  55.3           51   44,7

Immunohistochemical assays
--------------------------

The immunohistochemical expression of proteins related to the selected genes was evaluated by TMA. The expression levels of the markers p53, Bcl-2, Ki67, epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) were also evaluated. Histological sections (4 μm thick) were stained with hematoxylin-eosin and reviewed, and the sites for TMA sampling were also selected. TMA blocks were prepared using Beecher apparatus (Beecher Instruments, Silver Spring, MD, USA), according to the manufacturer's instructions. The TMA block sections were attached to the slides using an adhesive tape system (Instrumedics Inc., Hackensack, NJ, USA). The samples were cut to a thickness of 4 μm, and a small roller was used to press the section onto the tape. The tape with the attached histological section was then placed on a resin-coated slide (part of the adhesive system kit) and pressed with the same roller for better adherence. The slides were then placed under UV light for 20 min and were exposed to a solvent solution (TPC) for a further 20 min. The slides were dried, and the tape was removed. The sections were paraffin-embedded and stored in ideal cooling conditions.

Sections of TMA blocks were mounted onto glass slides coated with silane (3-aminopropyltriethoxysilane) and dried for 30 min at 37°C, deparaffinized with xylene and rehydrated through a series of graded alcohols. Endogenous peroxidase activity was blocked by incubating the sections in a bath of methanol containing 3% hydrogen peroxide for 20 min, followed by washing in distilled water. The sections were initially submitted to heat-induced epitope retrieval using citrate buffer (pH 9.0) in an uncovered pressure cooker (Eterna®, Nigro, Araraquara, Brazil). The slides were immersed in the buffer solution, and the pressure cooker was closed with the safety valve open; once the saturated steam was released, the safety valve was lowered until full pressurization was achieved. Endogenous peroxidase was blocked with 3% hydrogen peroxide (10 vol. hydrogen peroxide) for three washes of 10 min each. The slides were washed again in running distilled water, followed by 10 mM phosphate-buffered saline, pH 7.4, for 5 minutes. Primary antibodies were then applied, and the slides were incubated overnight at 8°C.

The following primary monoclonal antibodies were purchased from Abcam (Cambridge, MA, USA) and used at a 1:400 dilution: mouse anti-α6 integrin (100 μg), rabbit anti-β5 integrin (500 μl), mouse anti-α3 integrin (100 μg), mouse anti-αV integrin (100 μg), and mouse anti-α5 integrin (100 μl). The following non-ECM primary antibodies were also used: anti-p53 (1:300), anti-Bcl-2 (1:600), anti-VEGF (1:100), anti-Ki67 (1:500), and anti-EGFR (1:100).

Specimen classification based on immunohistochemical results
------------------------------------------------------------

Preliminary tests were performed to identify the optimal antibody concentrations and to select positive and negative controls using the dilution data supplied by the manufacturer.

After washing the primary antibody with phosphate-buffered saline, the slides were incubated with biotin-free polymer in the Advance ™ visualization system (DAKO) for 30 min. A freshly prepared solution containing 1 drop of DAB (3.3 - diaminobenzidine tetrahydrochloride; Sigma, St. Louis, Mo., USA) with 1 ml of substrate (DAKO) was applied for 5 min on each slide.

Tissue expression of markers was categorized dichotomously as either 'over-expression' or 'under-expression', according to the 'quick score' method \[[@B17],[@B18]\], which multiplies the percentage of stained cells (P) by the intensity of staining (I). The percentages of stained tumor cells were Scored as follows: 0 (absence of stained cells), 1 (\<25% stained cells), 2 (26--50% stained cells) and 3 (\>50% stained cells). Scores for the intensity of cell staining were as follows: 1 (mild intensity), 2 (moderate intensity) and 3 (intense staining). A gene product was thus considered to be over-expressed when the final score was \>4 (P × I = \>4), while markers with a final score ≤4 were considered to be under-expressed.

Stroma and tumor cells were not treated separately during immunohistochemical analysis, and only the expression levels of markers on tumor cells were considered for scoring (Figure [1](#F1){ref-type="fig"}).

Statistical analysis
--------------------

Data from real-time PCR were analyzed using the RT2 Profiler PCR Array Data Analysis program, version 3.4 (SABioscience, Qiagen) (<http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php>). Statistical associations between integrin gene and protein expression levels and clinicopathological factors were determined using non-parametric Mann--Whitney U tests for quantitative variables and χ^2^ tests for qualitative variables. When the χ^2^ assumptions were not met, Fisher's exact test was used.

###### 

Analysis of IHC expression of Integrins expression according to covariates in patients with CRC (n = 114)

     **Covariates**      **Categorization**   **Integrins**                                                                                                                   
  --------------------- -------------------- --------------- --------------- ----------- --------------- ------------ --------------- ----------- --------------- ----------- ---------------
           Age              \< 60 years           27/29           0.259         27/29         1.00         **49/7**    ***\<0.001***     30/26         1.000         30/26         0.851
       ≥ 60 years              35/23                              28/30                     **4/54**                       31/27                       33/25                  
         Gender                 Male              34/29           1.000         28/35         0.451         29/34          1.000         36/27         0.452         35/28         1.00
         Female                28/23                              27/24                       24/27                        25/26                       28/23                  
    Histological type          Adeno              54/43           0.601         48/49         0.502       **51/ 46**    ***0.003***    **61/36**    ***0.002***      53/44         0.684
        Mucinous                8/9                               7/10                      **2/15**                     **0/17**                      10/7                   
      Tumor grading          Low grade            56/44           0.401         50/50         0.397         48/52          0.569         57/43         0.083         57/43         0.394
       High grade               6/8                                5/9                         5/9                         4/10                         6/8                   
     Venous invasion           Absent           **58/35**     ***\<0.001***   **52/41**    ***0.001***      42/51          0.631       **61/32**   ***\<0.001***     54/39         0.239
         Present              **4/17**                          **3/18**                      11/10                      0**/21**                      09/12                  
   Perineural invasion         Absent           **62/44**      ***0.001***      52/54         0.781         49/57          1.000         59/47         0.142         60/46         0.464
         Present              **0/8**                              3/5                         4/4                          2/6                         3/5                   
     Clinical stage             I-II            **59/5**      ***\<0.001***   **53/11**   ***\<0.001***     28/36          0.572       **40/24**    ***0.038***    **49/15**   ***\<0.001***
         III- IV              **3/47**                          **2/48**                      25/25                      **21/29**                   **14/36**                

-/+ = Low/high expression; *Adeno.*,Adenocarcinoma. Significant values are bold.

The associations between integrin genes and the non-ECM markers EGFR, VEGF, p53, Bcl-2 and Ki67 (ordinal variables) were measured using the Spearman correlation coefficient. The Spearman coefficient may range from -1 to +1, and the closer the calculated value is to these extremes (-1 or +1), the greater the association between the variables \[[@B19]\].

The level of significance was set at 5% (*P* \< 0.05), and the data were analyzed using SPSS software (Statistical Package for Social Sciences; SPSS, Chicago, IL, USA), version 15.0. The Shapiro-Wilk test was used to verify that the data were normally distributed.

Results
=======

Integrin gene expression in colon cancer tissues analyzed by RT-PCR
-------------------------------------------------------------------

The *ITGA3* gene was significantly over-expressed in TNM III tumors compared with TNM I tumors (2.40 -fold regulation; *P* = 0.025). *ITGA5* was over-expressed in histological mucinous type compared with adenocarcinomas (1.25-fold regulation; *P* = 0.029), and under-expressed in patients aged over 60 years, compared with those under 60 (1.54-fold regulation; *P* = 0.016). The *ITGB5* gene was over-expressed in TNM III compared with TNM I stages (1.30-fold regulation; *P* = 0.042). The *ITGA6* gene was over-expressed in tumors with venous invasion compared with those without (1.42-fold regulation; *P* = 0.047), while the *ITGAV* gene was over-expressed in tumors with perineural invasion, compared with those without (1.37-fold regulation; *P* = 0.02). Regarding the degree of cell differentiation, there were no significant differences in expression levels of gene (grades I-II compared with grade III) . A summary of these results is shown in Table [2](#T2){ref-type="table"}.

###### 

Expression levels of integrins genes in relation to clinicopathological variables and immunohistochemical scores (p \< 0.05)

          **Integrin**         **Gene expression - group**   **Protein expression - group**    **Validation**
  ---------------------------- ----------------------------- -------------------------------- ----------------
               α6              Over - vascular invasion +    Over - vascular invasion +             Yes
        Over - mucinous        No                                                             
       Over - TNM III,IV       No                                                             
               αV              Over - neural invasion +      Over - neural invasion +               Yes
       Over - TNM III,IV       No                                                             
   Over - vascular invasion +  No                                                             
               α5              Over -- mucinous              Over - mucinous                        Yes
        Under - age \>60       Over -- age \>60              No                               
               β5              Over - TNM III                Over - TNM III,IV                      Yes
               α3              Over - TNM III                Over - TNM III,IV                      Yes
   Over- vascular invasion +   No                                                             

Immunohistochemical study of integrins in colon cancer tissues
--------------------------------------------------------------

Table [3](#T3){ref-type="table"} shows the frequencies of high and low expression of the gene products of interest for the 114 patients included in this study.

Regarding the degree of cell differentiation, there were no significant differences in expression levels of any proteins between tumors scored as immunohistochemical grades I-II compared with grade III (*P* \> 0.05). In terms of TNM staging, however, ITGB5, ITGAV, ITGA3 and ITGA6 proteins were significantly over-expressed in stages III and IV compared with stages I and II (*P* \<0.05).

In relation to the presence of peritumoral inflammatory infiltrate, there were no significant differences in expression levels of any of the evaluated proteins (*P* \> 0.05) in relation to the presence or absence of inflammatory infiltrate. Regarding the presence vs. the absence of venous invasion, however, ITGAV, ITGA3 and ITGA6 were significantly over-expressed in the presence of venous invasion (*P* \< 0.05). In addition, ITGAV was significantly over-expressed in tumors showing perineural invasion (*P* \< 0.05), and ITGA5 and ITGA6 were significantly over-expressed in mucinous-type tumors compared with adenocarcinoma (*P* \< 0.05).

There were no significant differences in expression levels between genders for any of the analyzed proteins (*P* \> 0.05). However, ITGA5 protein was over-expressed in patients under 60 years old compared with those over 60 years (*P* \< 0.05). Table [4](#T4){ref-type="table"} shows the results of immunoexpression of these markers according to the clinicopathological covariates studied.

For each integrin gene that was under- or over-expressed according to array tracking, the corresponding protein was analyzed by antigen-antibody reaction on TMA slides. Protein expression levels validated the RT-PCR results, with the exception of *ITGA5* expression in relation to age. A summary of these results is presented in Table [5](#T5){ref-type="table"}.

Relationship between integrin expression and epithelial markers
---------------------------------------------------------------

The associations between integrin genes and the epithelial markers EGFR, VEGF, p53, Bcl-2 and Ki67 were analyzed using the Spearman correlation coefficient. Significant associations were found between *ITGAV*/EGFR (r = 0.774; *P* \< 0.001), *ITGA3*/EGFR (r = 0.744; *P* \< 0.001) and p53/Ki67 (r = 0.875; *P* \< 0.001).

The Spearman correlation is presented in Table [6](#T6){ref-type="table"}.

###### 

Spearman coefficient correlation (r, two-tailed model) for associations between IHC expression of integrins proteins and other markers (n = 114)

                 **ITGB5**     **ITGA5**     **ITGAV**     **ITGA6**     **ITGA3**     **EGFR**      **VEGF**      **KI67**       **P53**      **BCL2**    
  ------------ ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- --------
   **ITGB5**         ρ           1,000         0,025         0,380         0,116         0,480         0,428        -0,049         0,104         0,057      -0,018
   Valor de p        .           0,791      **0,000\***      0,218      **0,000\***   **0,000\***      0,603         0,270         0,548         0,852     
   **ITGA5**         ρ           0,025         1,000        -0,100         0,199        -0,020        -0,003         0,086        -0,205        -0,193      0,018
   Valor de p      0,791           .           0,291      **0,034\***      0,832         0,976         0,366      **0,028\***   **0,040\***      0,853     
   **ITGAV**         ρ           0,380        -0,100         1,000         0,135         0,708         0,774        -0,103         0,262         0,215      -0,106
   Valor de p   **0,000\***      0,291           .           0,152      **0,000\***   **0,000\***      0,277      **0,005\***   **0,022\***      0,263     
   **ITGA6**         ρ           0,116         0,199         0,135         1,000         0,231         0,219         0,055         0,134         0,086      -0,088
   Valor de p      0,218      **0,034\***      0,152           .        **0,013\***   **0,019\***      0,559         0,154         0,366         0,352     
   **ITGA3**         ρ           0,480        -0,020         0,708         0,231         1,000         0,744         0,051         0,155         0,100      0,018
   Valor de p   **0,000\***      0,832      **0,000\***   **0,013\***        .        **0,000\***      0,587         0,101         0,288         0,853     
    **EGFR**         ρ           0,428        -0,003         0,774         0,219         0,744         1,000        -0,082         0,375         0,335      -0,054
   Valor de p   **0,000\***      0,976      **0,000\***   **0,019\***   **0,000\***        .           0,384      **0,000\***   **0,000\***      0,569     
    **VEGF**         ρ          -0,049         0,086        -0,103         0,055         0,051        -0,082         1,000        -0,165        -0,150      0,334
   Valor de p      0,603         0,366         0,277         0,559         0,587         0,384           .           0,080         0,111      **0,000\***  
    **KI67**         ρ           0,104        -0,205         0,262         0,134         0,155         0,375        -0,165         1,000         0,875      -0,124
   Valor de p      0,270         0,028      **0,005\***      0,154         0,101      **0,000\***      0,080           .        **0,000\***      0,189     
    **P53**          ρ           0,057        -0,193         0,215         0,086         0,100         0,335        -0,150         0,875         1,000      -0,107
   Valor de p      0,548      **0,040\***   **0,022\***      0,366         0,288      **0,000\***      0,111      **0,000\***        .           0,256     
    **BCL2**         ρ          -0,018         0,018        -0,106        -0,088         0,018        -0,054         0,334        -0,124        -0,107      1,000
   Valor de p      0,852         0,853         0,263         0,352         0,853         0,569      **0,000\***      0,189         0,256           .       

Discussion
==========

There is considerable evidence to implicate genetic alterations in the rapid progression of several types of malignant tumors from the early to more advanced stages. Abnormal signaling of molecules may activate genes and thus trigger dissemination and metastasis. The identification of these altered molecules and their correlations with clinical and pathological stages may help to elucidate the mechanisms involved in this processes.

Koivisto et al. \[[@B20]\] suggested that the ECM has a decisive influence on tumor behavior, especially in processes of proliferation, progression and tumor cell invasion. These interactions are mediated by integrins, which play an important role in the development of tumor invasion and metastasis. This study highlighted the roles of the integrin membrane receptors, which are the most-studied and well-understood cell adhesion molecules \[[@B4],[@B8],[@B21]\]. The extracellular portion of the integrin is known to bind to ECM proteins, while the intracellular portion connects to cytoskeletal elements such as actin filaments. This connection reinforces the integrity of tissues and cell adhesion, and stabilizes cellular protrusions during migration. This connection also represents a signaling pathway that can transmit information to key processes such as transcriptional control, cell death, proliferation and migration \[[@B22]\]. Furthermore, integrins have been shown to be differentially expressed during tumor growth and progression, making them potential targets for the diagnosis and therapy of cancer \[[@B14]-[@B16],[@B23]\].

In this study, we detected over-expression of the genes for α3 and β5 integrins in more advanced tumors, in stages III compared with stage I, which represent non-metastatic tumors. This observation was confirmed by TMA protein analysis, suggesting a relationship between these integrins and tumor progression and dissemination. According to Jinka et al. \[[@B24]\], over-expression of integrins α3, α5 and α6 was directly related to the progression of various types of malignant tumors. Haier et al. \[[@B25]\] studied the expression of α2, α3, α5 and α6 integrins by immunohistochemistry in cell lineages from metastatic colorectal liver carcinoma, and showed over-expression of α2 and α3 integrin in relation to dissemination potential. Another immunohistochemical study by Toquet et al. showed higher expression of α5 integrin in poorly differentiated cells in grade-III tumors, compared with grades I and II \[[@B26]\]. This study demonstrated a significant relationship between α5 integrin expression and mucinous histological type vs. adenocarcinoma, the latter of which has a better prognosis.

A recent cell-culture study of human breast cancer and normal epithelial tissue showed an involvement of β5 integrin in tumor progression and invasion in terms of altered adhesion, cell architecture, and differentiation, and noted that inhibition of this integrin significantly reduced breast carcinoma cell invasion \[[@B27]\]. α6 Integrin regulates multiple cellular functions, including the development of cell invasion, migration and tumor progression \[[@B28]\]. However, to the best of our knowledge, the current study is the first to demonstrate a correlation between α6 integrin gene over-expression and venous invasion, thus connecting tumor spread with hyper-expression of this integrin. Further studies are needed to confirm these findings. A recent study \[[@B29]\] examined breast cancer cell lineages in rats by RT-PCR and flow cytometry, and concluded that α6 integrin worked as a promoter for cell metastasis and accelerated cell proliferation, indicating its involvement in tumor progression.

Neural invasion was associated with a significantly lower survival rate and an increased recurrence rate in patients with rectal cancer stage III and IV \[[@B30]\]. In the present study, expression of the *ITGAV* gene was significantly related to the presence of perineural invasion (*P* = 0.02), as confirmed by TMA analysis. Although some integrin subtypes have been shown to be associated with perineural invasion in prostate cancer \[[@B31]\] and carcinomas of the head and neck \[[@B32]\], no previous study has demonstrated a relationship between over-expression of *ITGAV* and the presence of perineural invasion in CRC.

We also examined the associations between integrin protein expression and expression of selected epithelial markers. EGFR showed a strong correlation with αV integrin and a moderate correlation with α3 integrin (both *P* \< 0.05). Other studies have suggested that integrins may also modulate the intracellular recycling of growth factor receptors such as EGFR \[[@B33]\] and VEGFR \[[@B34]\]. Other authors reported that the EGFR-integrin interaction seen in pancreatic cancer also increased the migration of colon cancer cells through the integrins α3β1 and α6β4, and acted in hepatocellular carcinoma through integrins α1β1 and α2β1 \[[@B35],[@B36]\].

Conclusions
===========

Increased expression levels of *ITGA6* and *ITGAV* are related to venous invasion and neural infiltration, respectively, while over-expression of *ITGB5* and *ITGA3* are associated with stage III (TNM), and over-expression of *ITGA5* correlates with the presence of mucinous-type malignant neoplasias.

Further follow-up studies, preferably with a controlled prospective design, are necessary to establish the roles of integrins as potential biomarkers that could predict disease extent or outcome, and possibly contribute to the management of patients with CRC.
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